US 11,834,491 B2
Arginine-free TNFR:FC-fusion polypeptide compositions
Kevin Maloney, Nashua, NH (US); Ke Gong, Lexington, MA (US); and Roy Alston, Framingham, MA (US)
Assigned to Biogen MA Inc., Cambridge, MA (US)
Filed by Biogen MA Inc., Cambridge, MA (US)
Filed on Mar. 30, 2021, as Appl. No. 17/216,769.
Application 17/216,769 is a continuation of application No. 14/128,846, granted, now 10,995,130, previously published as PCT/US2012/044988, filed on Jun. 29, 2012.
Claims priority of provisional application 61/504,110, filed on Jul. 1, 2011.
Prior Publication US 2021/0309719 A1, Oct. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 47/68 (2017.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01); A61K 47/02 (2006.01); C07K 19/00 (2006.01); C07K 14/715 (2006.01); A61P 29/00 (2006.01); C07K 14/705 (2006.01); C07K 14/525 (2006.01); C07K 16/24 (2006.01)
CPC C07K 14/7151 (2013.01) [A61K 9/0019 (2013.01); A61K 38/1793 (2013.01); A61K 47/26 (2013.01); A61K 47/68 (2017.08); C07K 19/00 (2013.01); A61K 47/02 (2013.01); A61P 29/00 (2018.01); C07K 14/525 (2013.01); C07K 14/70578 (2013.01); C07K 16/241 (2013.01); C07K 2319/30 (2013.01)] 18 Claims
 
1. A syringe comprising a composition, wherein the composition comprises:
an isolated polypeptide that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of a human IgG1 at a concentration of 10 mg/mL to 100 mg/mL;
aqueous buffer at a concentration of less than 25 mM, wherein the aqueous buffer is sodium phosphate, potassium phosphate, sodium or potassium citrate, maleic acid, ammonium acetate, tris-(hydroxymethyl)-aminomethane (tris), acetate, diethanolamine, or a combination thereof;
salt at a concentration of greater than 100 mM; and
a sugar,
wherein the composition does not contain free amino acids.